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Background: Patients with malignant mesothelioma have a poor prognosis and only 40% respond to first line
treatment; a combination of pemetrexed and cisplatin or carboplatin. We used primary malignant mesothelioma
cells and an ex vivo chemosensitivity assay with future purpose to predict best choice of treatment. The clinical
outcome of these patients might be predicted by measuring drug sensitivity.
Methods: Pleural effusions containing primary malignant mesothelioma cells were received from the diagnostic
routine. We characterized and tested the chemosensitivity of 18 malignant samples and four benign samples from
16 different patients with pleural effusions. Cells were seeded in a 384-well plate for a robotized ex vivo testing of
drug sensitivity to 32 different drugs. The primary cells were further characterized by immunocytochemistry to
evaluate the proportion of malignant cells and to study the RRM1 and ERCC1 reactivity, two proteins associated
with drug resistance.
Results: We observed great individual variability in the drug sensitivity. Primary cell isolates were affected by between
one and ten drugs, and resistant to the remaining tested drugs. Actinomycin D and daunorubicin were the two drugs
effective in most cases. Adjusting efficiency of individual drugs for varying proportion of tumor cells and to the average
effect on benign cells correlated with effect of pemetrexed, cisplatin and survival time. General drug sensitivity,
proportion of malignant cells and reactivity to RRM1 correlated to each other and to survival time of the patients.
Conclusions: The proportion of malignant cells and RRM1 reactivity in the pleural effusions correlate to drug sensitivity
and survival time. The variability in response to the commonly used chemotherapies emphasizes the need for tests that
indicate best individual choice of cytotoxic drugs. The efficiency of the obtained results should preferably be corrected
for admixture of benign cells and effects of given drugs on benign cells.
Keywords: Malignant mesothelioma, Pleural effusions, Primary cells, Chemotherapy, Ex vivo chemosensitivity, Cytotoxic
drugs, RRM1, ERCC1 and Individualized treatmentBackground
Malignant mesothelioma (MM) is a tumor originating
from the mesothelial tissue. The predominant cause is
asbestos exposure and therefore the tumor mainly af-
fects the pleura [1,2]. Accumulation of fluid in the
pleural cavity is common in malignant pleural meso-
thelioma and causes initial symptom as dyspnea [3]. To* Correspondence: katalin.dobra@ki.se
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unless otherwise stated.alleviate symptoms the fluid is drained by pleurocent-
esis. The collected pleural effusion can be used to
establish the diagnosis, based on its content of exfoli-
ated malignant and reactive benign mesothelial cells,
inflammatory cells and associated excreted proteins
and carbohydrates [4].
MM is a highly therapy resistant tumor with a poor
prognosis and the mean overall survival time is 12
months [5]. Chemotherapy is often the only treatment
option available but the current first line chemotherapy,
a combination of pemetrexed and cisplatin or carboplatin,Ltd. This is an Open Access article distributed under the terms of the Creative
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vival with merely three months [6]. While a number of
drug combinations have shown promising results, there is
no standardized second line chemotherapy [7]. Thus, in
case of treatment failure drugs like doxorubicin and gemci-
tabine are sometimes used as second line treatment. Pa-
tients that respond to chemotherapy have the longest
overall survival time, highlighting the importance of accur-
ate drug selection [8].
Excision repair cross-complementing rodent repair
deficiency, complementation group 1 (ERCC1) and
Ribonucleotide reductase large subunit M1 (RRM1) are
two proteins involved in drug resistance. ERCC1 is a
main player in the nucleotide excision repair, a DNA re-
pair pathway which has been suggested to clear DNA
crosslinks caused by platinum drugs [9]. RRM1 is a sub-
unit of ribonucleotide reductase (RNR), a protein neces-
sary for DNA synthesis. RNR has been shown to be
completely inactivated by gemcitabine in vitro [10].
Several studies show a link between ERCC1 and RRM1
alone or in combination with other biomarkers to drug
sensitivity, progression-free survival or overall survival
in lung cancer [11,12] and in MM [13-15] We have
also seen indication that ERCC1 and RRM1 immuno-
reactivity may explain the sensitivity of MM cell lines
to carboplatin [16]. However, these proteins still need
further investigation [17].
Hyaluronan and mesothelin are two established bio-
markers for MM [18-20]. Levels of these biomarkers
have been associated with prognosis, perhaps as an indi-
cation of tumor cell differentiation [20,21]. Hyaluronan
is an extracellular matrix polysaccharide involved in cell
motility among other processes and is believed to effect
tumor aggressiveness [22]. In MM, hyaluronan synthase
1, 2 and 3 are up-regulated and hyaluronan receptors,
normally not found on mesothelial cells, are expressed
[23,24]. Mesothelin is a cell membrane protein normally
present on mesothelial cells and its exact function is
unknown [25-27]. Hyaluronan and mesothelin together
can discriminate between metastatic adenocarcinoma
and MM with high specificity [18].
The aim of this study was to use primary MM cells in
an ex vivo chemosensitivity assay with the future pur-
pose to predict the best choice of treatment and predict
outcome for individual MM patients. We therefore stud-
ied pleural effusions with respect to the drug sensitivity
of tumor cells and immunoreactivity of two proteins as-
sociated with drug resistance, ERCC1 and RRM1. Simul-
taneously, effusion supernatants were examined for their
content of the diagnostic biomarkers hyaluronan and
mesothelin. These results were then correlated to the
overall survival time of patients included in this study,
assuming that general drug sensitivity associates with a
less advanced tumor.Methods
Inclusion criteria and culturing of mesothelioma cells
In this study primary cells from twelve patients diag-
nosed with malignant mesothelioma, benign mesothelial
cells from pleural effusions from four patients with no
malignant diagnosis and five MM cell lines were in-
cluded (for demographic data, see Additional file 1). All
effusions but three were received before patient treat-
ment was initiated. All effusions were obtained from the
diagnostic routine at the Department of Pathology and
Cytology, Karolinska University Hospital in Huddinge,
Sweden. The material was collected between 2007 and
2012 and the study was approved by the regional ethics
committee in Stockholm.
All MM diagnoses were established by a combination
of cytomorphological examination, immunocytochemistry
(ICC) and biomarker analysis. The cytomorphological cri-
teria for malignant effusions suggesting mesothelioma are:
presence of abnormal cells, high content of cells and cell
aggregates, presence of enlarged mesothelial cells, cell
engulfment and presence of cells with macronucleoli. The
immunocytochemical analysis comprised of staining pro-
file for Epithelial membrane antigen (EMA), Calretinin,
HBME-1 and Mesothelin supporting the mesothelial ori-
gin of cells, and negative reaction with Carcinoembryonic
antigen (CEA), BerEp4 and Thyroid transcription factor-1
excluding a metastatic tumor. High levels of hyaluronan
(>75 μg uronic acid/ml) indicates MM [28]. In cases were
these analyses were inconclusive Fluorescence in situ
hybridization (FISH) was performed, to identify cell popu-
lation with aneuploidy and/or homozygous deletion of
Cyclin-dependent kinase inhibitor 2A (CDKN2A) gene,
coding for the p16INK4A protein. In some cases electron
microscopy was also used to obtain a correct diagnosis.
This approach has been shown to be effective in previous
studies by us and others [29-31]. All patients diagnosed
with MM were treated with pemetrexed and carboplatin.
All benign effusions were derived from patients with
no sign of malignant disease involving the pleural cavity.
They included admixture of reactive mesothelial cells
and inflammatory cells, without further information of
their etiology and without any morphological sign of
malignancy. All four patients with benign diagnoses
were still alive and without diagnosis of malignancy six
months after the collection of fluids.
For culturing of primary cells the effusions were cen-
trifuged at 400 g, 5 min and cells were seeded in Iscove’s
modified Dulbecco’s medium (Sigma-Aldrich, St. Louis,
USA) containing 20% FBS (Fetal Bovine Serum, Invitrogen,
Carlsbad, USA), 0.2% Gentamicin (Invitrogen), 1% Peni-
cillin Streptomycin (Invitrogen) and 1% L-glutamine
(Invitrogen). To study the effect of long time culturing
on drug sensitivity, two of the samples were cultured up
to 18 passages before experiments were performed, with






Aziridine Mitomycin C 0.3 - 0.6
Tetrazine Dacarbazine 16.7
Platinum drugs Cisplatin 0.2









Mercaptopurine 46.3 - 69.4
Fludarabine 20.8 - 41.7
Cladribine 0.8






Docetaxel 8.3 - 16.7
Vinca
alkaloids
Vinblastine 0.2 - 8.3
Vincristine 0.2 - 0.8
Vinorelbine 1.7 - 8.3
Topoisomerase
inhibitors
Type I Topotecan 0.2 -1.7
Irinotecan 16.7
Type II Etoposide 16.7
Amsacrine 4.2
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stantial amounts of papillary groups; these groups were
separated from disassociated cells by shaking the cell
flasks after 24 hours, collecting the floating cells and
reseeding them in new flasks (summarized in Table 1).
Five different MM cell lines were included in this
study. MM cell lines: STAV-AB, STAV-FCS and ZL-34
cells were kindly provided by Julius Klominek [32,33].
M-14-K and M-28-K cells were kindly provided by
K. Linnainmaa [34]. The STAV-AB cells were grown
in Gibco RPMI 1640 medium with 25 mM HEPES buffer
(Invitrogen) and 1% L-glutamine and 10% human AB-
serum. The STAV-FCS, ZL-34, M-14-K and M-28-K cells
were cultured in Gibco RPMI 1640 medium with 25 mM
HEPES buffer and 1% L-glutamine, 5% FBS and 5% BS
(Bovine Serum, Invitrogen).
Cytotoxicity assay
The primary mesothelial cells and cell lines were grown
to confluency, adherent cells were trypsinized (Invitrogen)
and 3000–6000 cells per well were re-seeded in the pri-
mary cell culture medium OmniSanguine in a 384-well
plate for a robotized ex vivo testing of drug sensitivity for
72 hours, as previously described [35,36]. Briefly, prior to
seeding, plates were prepared with 32 different drugs
(highest concentrations used summarized in Table 2), dis-
tributed to the wells in triplicates and in four different
concentrations (diluted 1:1, 1:5, 1:25 and 1:125 in dimethyl
sulfoxide) covering a clinically relevant concentration
span. Control cells were grown on the same plate, in the
same conditions but without the addition of a drug. After
72 hours, VitalDye (Biomarker Ltd, Gödöllő, Hungary)
was added to stain living and dead cells, respectively. The
amounts of living and dead cells were measured using
Qantascope HexascopeHTP automated scanning and ana-
lyzing system (Qantascope Biotech, Stockholm, Sweden)Table 1 Growth properties of primary cell cultures
Primary cell isolate Culture identity Growth property
MMi3 MMi3 Primary cell culture
MMi4 Grown for eighteen passages
MMi6 MMi6 Primary cell culture
MMi7 Grown for seven passages
MMi17 MMi17 Adhered disassociated cells
MMi18 Papillary groups
MMi8 MMi8 Primary cell culture
MMi9 Seeded the following day
MMi15 MMi15 Papillary groups
MMi16 Adhered disassociated cells
Primary cells were cultured for several passages, divided into adherent cells
and papillary groups or seeded on the following day. MMi6 and MMi17 are
two effusions from the same patient.
Proteasome
inhibitor
Bortezomib 0.2 - 2.9
Multifunctional
drugs
Anthracycline Daunorubicin 4.2 - 16.7
Doxorubicin 0.8 - 1.7
Epirubicin 1.7
Other Actinomycin D 0.1 - 0.4
Bleomycin 2.5 - 12.5*
Enzyme Asparaginase 0.6 - 8.3*
Corticosteroid Prednisolone 16.7 - 41.7
Drugs are divided according to their mechanism of action.
* = IU/ml.[35,36]. Images were captured using the QantCapture soft-
ware and amount of living and dead cells was counted by
the QantCount software [35-37].
The calculation of the drug efficiency was based on
the different degrees of sensitivity at each different
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counting of the survival percentage and the drug con-
centration as follows:
Drug efficiency ¼
100−% live cells at 1 : 125 dilutionð Þ  ln 125ð Þþ
100−% live cells at 1 : 25 dilutionð Þ  ln 25ð Þþ
100−% live cells at 1 : 5 dilutionð Þ  ln 5ð Þþ
100−% live cells and undilutedð Þ
ln 125ð Þ þ ln 25ð Þ þ ln 5ð Þ þ 1
The proportion of tumor cells varied considerably in the dif-
ferent cell isolates. To compensate for this, the above described
drug efficiency was corrected according to the proportion of
tumor cells present and effect on benign cells (“adjusted drug
efficiency”), assuming that the benign cells were affected by
the individual drugs in the same magnitude as the corres-
ponding average from the four benign control samples.
Adjusted drug efficiency ¼
Drug efficiency– proportion benign cells  average effect on benign cells
Proportion of tumor cells
Both estimates for drug efficiency were correlated with
patient overall survival as surrogate factor, comparing
their respective correlation coefficients.
Immunocytochemistry
Cytospin preparations of primary MM cells were per-
formed on SuperFrost Plus glass slides (Thermo Fisher
Scientific Inc, Waltham, MA, USA), fixed in H2O with
25% ethanol, 25% methanol, 3% polyethylene glycol
(PEG) and stored at −20°C. Before staining, PEG was ex-
tracted by decreasing concentrations of ethanol in H2O.
Immunostaining was performed in a Leica BOND-III
automated IHC (see Table 3) with relevant isotype
controls, diluted in BOND Primary Antibody Diluent
(Leica Microsystems GmbH) and detected with the
Bond Polymer Refine Detection kit (Leica Microsystems
GmbH) or Bond Polymer Refine Red Detection kit (Leica
Microsystems GmbH) according to the manufacturer’s
protocol. Briefly, for detection of Desmin, EMA and CD45
slides were pretreated 5 min in a citrate buffer pH 6.0
(Bond Epitope Retrieval Solution 1, Leica Microsystems
GmbH), while an EDTA buffer pH 9.0 (Bond EpitopeTable 3 Antibodies used in the experiments
Target Abbreviation
Desmin Desmin
Epithelial membrane antigen EMA
Leukocyte common antigen CD45
Excision repair cross-complementing rodent repair deficiency,
complementation group 1
ERCC1
Ribonucleotide reductase M1 RRM1
Suppliers: 1 = Leica Microsystems GmbH, Wetzlar, 2 = Dako, Glostrup, Denmark, 3 =Retrieval Solution 2, Leica Microsystems GmbH) was
used for 20 min for ERCC1 and RRM1 staining. En-
dogenous peroxidase activity was abolished with 3%
hydrogen peroxide in H2O. Slides were then treated with
primary antibodies for 30 min where after secondary IgG
was added and incubated for 15 min. Following addition
and 15 min incubation with a poly-HRP, bound anti-
bodies were visualized by Diaminobenzidine treatment
for 10 min and followed by 10 min counterstain with
hematoxylin. Double staining was performed for Desmin
and EMA, to distinguish Desmin positive reactive meso-
thelial cells from malignant cells. EMA was detected as
described above whereafter Desmin was detected with
a primary antibody, a secondary IgG, incubated with
poly-AP and developed with Fast red. All slides were
independently evaluated by two experienced cyto-
pathologists (KD and AH) who rated the amount of
malignant cells from 0-100% and the staining intensity
from 0 to 3 (0 representing no staining and 3 represent-
ing strong staining). Discrepant cases were re-evaluated
and discussed to reach consensus.
Fluorescence in situ hybridization
In cases where it was difficult to estimate the proportion
of malignant cells by immunocytochemistry, we deter-
mine this more accurately using the UroVysion bladder
cancer kit (Abbott Laboratories, Green Oaks, IL, USA).
The kit was used on the primary cell isolates to assess
aneuploidy as previously described [30]. Briefly, primary
MM cells were incubated in trypsin to dissociate pos-
sible cell groups, washed and pellet was spun down on
SuperFrost glass slide (Thermo Fisher Scientific Inc).
Slides were fixed in acetic acid and methanol, kept 2
min in saline sodium citrate (SSC) solution at 73°C and
then incubated 10 min in 0.01 M HCl containing 0.01%
Pepsin. After washing the slides the nuclear membranes
were stabilized with 1% formaldehyde in 0.01 M MgCl2
and dehydrated with increasing concentrations of etha-
nol. The four directly labeled DNA-probes that hybridize
to the centromere region on chromosomes 3, 7 and 17
and to the CDKN2A gene at 9p2, which codes for the
p16INK4A protein, were added to the slides, coverslipped,
sealed with rubber cement, and placed in a programmedAntibody Dilution Supplier Product code
Mouse monoclonal 1:50 1 NCL-DES-DERII
Mouse monoclonal (clone E29) 1:800 2 M 0613
Mouse monoclonal 1:400 1 NCL-LCA
Mouse monoclonal Ab-2 (clone 8 F1) 1:200 3 MS-671
Rabbit polyclonal 1:50 4 Ab81085
Thermo Fisher Scientific Inc, Waltham, MA, USA. 4 = Abcam, Cambridge, UK.
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ber was then removed and slides were stringency washed
in SSC with Igepal (Sigma-Aldrich), heated to 73°C, incu-
bated in SSC with Igepal, washed and dried. Finally, cells
were stained with 4′,6-diamidino-2-phenylindole and
coverslipped. Stainings were evaluated by a cytotechnician
(AC) whereby at least 100 cells for each slide were
counted, making it possible to determine the proportion
of malignant cells. A cell was considered malignant if the
number of centromeric probes was increased for at least
two of the chromosomes or if fluorescent signal for the
CDKN2A gene was missing.
Biomarkers
Levels of mesothelin (N-ERC) and hyaluronan were mea-
sured in the pleural effusions as part of the diagnostic
routine and subsets of these results have previously been
presented [18]. Measurements were done with Enzyme-
Linked Immunosorbent Assays (ELISA) or by High-
Performance Liquid Chromatography for hyaluronan, as
previously described [18,28]. For mesothelin the ELISA kit
was bought from Immuno-Biological Laboratories Co.,
Ltd. (Fujioka, Japan, product code 99666/7–16 assay) and
for Hyaluronan from Corgenix (Broomfield, CO, USA,
product code 029–001).
Statistical analyses
To examine different possible correlations, linear regres-
sion analyses were performed. A Log-rank (Mantel-Cox)
test with two-tailed p-values was performed to compare
two survival curves in the Kaplan-Meier plot. To further
evaluate the effect of drug dilutions in the cytotoxicity
assay, sensitivity score was defined as the sum of all drug
effects on a primary cell sample, where sensitivity to the
highest drug concentration was defined as 1 (1:1), the
first dilution as 2 (1:5), the second dilution as 3 (1:25)
and the third dilution and lowest concentration as 4
(1:125). Comparisons between subgroups were performed
with an unpaired t-test with two-tailed p-values.
Results
Great variability in chemosensitivity of primary cell samples
The amount of living cells after treatment was normal-
ized to amount of living control cells (Figure 1). All cases
with less than 50% dead cells at the highest concentration
were defined as resistant. The figure also grades the
sensitivity with increasing red color when lower drug
concentrations kill more than 50% of the cells. A great
individual variability in the drug sensitivity between the
different cell cultures was observed. The most resistant
cells (MMi3, MMi18, MMi15 and MMi16) were affected
by one drug and the most sensitive (MMi17, MMi4,
MMi5 and MMi6) by ten drugs. Some drug effects could
be seen also on the four benign samples, particularlydrugs affecting proliferating cells. The five cell lines dis-
played a similarly large variability in their drug sensitivity,
corresponding with effects seen on primary cells.
Actinomycin D and daunorubicin were the two
most effective drugs, affecting 10 of the 18 malignant
cell cultures, although some of these drugs also af-
fected two or three of the benign samples. The tax-
anes (paclitaxel and docetaxel), the vinca alkaloids
(vinblastine, vincristine and vinorelbine) and the anthra-
cyclines (daunorubucin, doxorubicin and epirubicin)
were the most potent groups of drugs. Surprisingly the
effect of bortezomib, cisplatin, carboplatin and peme-
trexed was limited, even though pemetrexed was only
tested on 50% of the samples.
The proportion of effective drugs correlated to
proportion of malignant cells
The proportion of malignant cells in the primary cell
isolates ranged between 10-98% and they inversely cor-
related to the proportion of effective drugs (p = 0.037)
while the correlation to the overall survival of the pa-
tients was not statistically significant (Figure 2A-B).
The survival time, however, correlated to the propor-
tion of effective drugs (p = 0.036), to the sensitivity score
(p = 0.0054) but not to the drug efficiency and adjusted
drug efficiency (Figure 2C-E). Kaplan-Meier analysis of
proportion of malignant cells and proportion of effective
drugs showed a tendency of longer survival time for pa-
tients with less malignant cells and with cell isolates
effected by more drugs, compared to those with higher
amount of malignant cells and lower amount of effective
drugs (p = 0.15, Figure 2F).
For nine patients, we could study the average effi-
ciency normalized for the varying proportion of malig-
nant cells in the culture and for the effect of the
respective drug on the benign control cells. This correc-
tion improved the predictive value of drug efficiency for
survival time (p = 0.12, Figure 2E). Similar adjustment
for each drug increased the explanatory values for effi-
ciency, using survival time as correlating surrogate fac-
tor. The sensitivity profile changed accordingly (Table 4
and Figure 3). Carboplatin, cisplatin and pemetrexed
affected only one malignant cell sample each, while gem-
citabine and doxorubicin affected four isolates each.
Adjusting the drug efficiency for pemetrexed, cisplatin
and doxorubicin increased the tendency to correlate
with survival, with increased coefficient of determination
and decreased p-values (p = 0.09, p = 0.05 and p = 0.17,
respectively).
Cytoplasmatic staining of RRM1 correlated to proportion
of effective drugs
All samples were stained for RRM1 and ERCC1
(Figure 4A-D), evaluating the staining of the malignant
Figure 1 Chemosensitivity of mesothelioma cells. Eighteen malignant cell isolates arranged according to their proportion of malignant cells,
four benign cell isolates and five cell lines with a pure malignant cell populations to the right. Benign samples in middle on grey background.
R = Resistant, more than 50% of cells alive in highest drug concentration. Red color marks a sample where less than 50% of cells were alive. An
increasing red color represents sensitivity to an increased drug dilution (1:1, 1:5, 1:25 and 1:125).
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the number of effective drugs (p = 0.0037) but not to the
survival time (Figure 5A-B). Primary cell cultures with a
higher ICC score for RRM1 were more resistant to the
antimicrotubule agents (except paclitaxel), topotecan,
hydroxyurea, gemcitabine, methotrexate, bleomycin and
doxorubicin, compared to those with a lower ICC score.
ERCC1 staining was not correlated to the proportion
of effective drugs or the survival time of the patients
(Figure 5C-D).
Hyaluronan and mesothelin
Hyaluronan and mesothelin values varied greatly be-
tween the different patients and different samples.
Hyaluronan levels correlated to the RRM1 cytoplas-
matic staining of the twelve patient samples (p = 0.024)
but not to the survival time (Additional file 2A-B).
No correlation was found for mesothelin (Additional
file 2C).
Aneuploidy and p16INK4A deletion
FISH was performed on nine cases and cells with an-
euploidy were found in all of them. In six of these a
homozygous deletion of 9p21 band could be demon-
strated, but presence of this did not correlate to pa-
tient data, drug sensitivity of cells or RRM1 and ERCC1
staining.Proportion of malignant cells correlates to RRM1 staining
and ex vivo drug effect
When dividing the results into two groups, according
to the amount of malignant cells, the cytoplasmatic
staining of RRM1 was stronger in the group with the
higher amount of malignant cells (p = 0.022). The
sensitivity score and proportion of effective drugs was
higher in the group with the lower proportion of
malignant cells (p = 0.0425 and p = 0.027). A split of
the results into two groups, according to proportion
of effective drugs, presented a significant difference
between the two groups, were the proportion of ma-
lignant cells was lower and the RRM1 cytoplasmatic
staining weaker in the group with the sensitive sam-
ples (p = 0.017 and p = 0.022). Dividing the results in
two groups, according to levels of hyaluronan, resulted
in a significant difference in the RRM1 cytoplasmatic
reactivity, stronger in the group with the higher hyalu-
ronan values (p = 0.022). With a similar categorization
according to mesothelin levels, no correlation was
found.
When separating the results into two groups, accord-
ing to the survival time or according to the sensitivity
score, no significant correlations were found. The six
samples with more malignant cells showed no corre-
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Figure 2 Correlation between proportion of effective drugs, percent malignant cells and survival time. Correlations of the proportion of
effective drugs, drug efficiency, survival time, percent of malignant cells and sensitivity score plotted in A-D. Each data point in blue represents
one patient, result from the linear regression analysis are presented in red. The drug efficiency is presented in red and adjusted drug efficiency in
blue, with data points for each patient and linear regression analysis (E). Kaplan-Meier analysis presents survival time according to proportion of
malignant cells in samples and proportion of effective drugs (F). Statistical significance was accepted at p < 0.05 and was seen for proportion of
effective drugs and percent of malignant cells (A), proportion of effective drugs and survival time (C) and sensitivity score and survival time (D).
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The importance of how cultures were isolated and
possible change during tumor progression was studied
(Table 1). When a primary culture (MMi3) was kept for
18 passages (culture MMi4) we could see a decrease in
the RRM1 staining, while ERCC1 staining remained.
Simultaneously the proportions of effective drugs in-
creased from 4% to 36%.
Similarly MMi6, obtained from a patient with long
term survival, was also tested after seven passages asMMi7. A second sample was obtained from the same
patient four years later. This second cell isolate was sep-
arated in two fractions, the first (MMi17) consisting of
cells adhering after overnight culture and the second
(MMi18) representing poorly adhering papillary groups.
Similarly another sample was grown out as adhering or
papillary cell groups (MMi16 and MMi15, respectively).
The early isolates (MMi6 and MMi7) showed the same
RRM1 and ERCC1 staining; also here the drug sensitiv-
ity was lost after prolonged culture. When comparing






R2 p-value R2 p-value
Pemetrexed 0.36 0.40 0.84 0.09
Chlorambucil 0.14 0.37 0.42 0.08
Hydroxyurea 0.08 0.47 0.32 0.11
Cisplatin 0.46 0.14 0.67 0.05
Doxorubicin 0.05 0.55 0.25 0.17
Paclitaxel 0.24 0.18 0.40 0.07
Asparaginase 0.17 0.27 0.32 0.11
Etoposide 0.00 0.95 0.14 0.32
Docetaxel 0.28 0.14 0.39 0.07
Vinblastine 0.00 0.98 0.08 0.46
Cytarabine 0.08 0.47 0.15 0.30
Vincristine 0.01 0.79 0.07 0.49
Gemcitabine 0.00 0.99 0.05 0.57
Bleomycin 0.37 0.08 0.41 0.06
Cladribine 0.37 0.08 0.38 0.08
Fludarabine 0.01 0.85 0.01 0.81
Oxaliplatin 0.04 0.59 0.04 0.59
Dacarbazine 0.33 0.42 0.33 0.42
Fluorouracil 0.04 0.58 0.04 0.60
Carboplatin 0.05 0.56 0.03 0.63
Topotecan 0.56 0.02 0.54 0.03
Bortezomib 0.05 0.55 0.03 0.64
Vinorelbine 0.03 0.67 0.00 0.96
Methotrexate 0.60 0.01 0.57 0.02
Actinomycin D 0.20 0.23 0.14 0.32
Daunorubicin 0.13 0.34 0.07 0.48
Mercaptopurine 0.11 0.47 0.05 0.63
Prednisolone 0.48 0.04 0.42 0.06
Epirubicin 0.36 0.09 0.22 0.20
Mitomycin C 0.29 0.13 0.05 0.57
For each individual drug a linear regression analysis was performed comparing
survival time and drug efficiency or adjusted drug efficiency. The explanatory
value (R2) and p-values are sorted according to the largest gain in explanatory
value when adjusting the drug efficiency. Statistically significant departure of
the slope from 0 was accepted at p < 0.05 and were found for prednisolone
and drug efficiency as well as for topotecan and methotrexate, both for drug
efficiency and when adjusting the drug efficiency.
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and RRM1 staining was similar, while the ERCC1 re-
activity was higher and the number of effective drugs
much lower in the isolate consisting of papillary tumor
fragments (only one compared to ten for the primarily
adhering cells). Corresponding differences were not
seen, comparing the MMi15 and MMi16 cell isolates.When looking at all four isolates from this patient, the
proportion of malignant cells increased from 20% to 60-
70% four years later. The RRM1 staining also increased,
while ERCC1 of adherent cells decreased. The amount
of effective drugs was high in MMi6 and MMi17 and
low in MMi7 and MMi18. The biomarker levels (hyalur-
onan and mesothelin) were largely increased during the
four years between the samples.
To test the effect of delayed seeding of cells, an aliquot
of MMi8 was also seeded the following day (MMi9,
Table 1). When comparing these two cultures we could
see a decrease in number of effective drugs (from six
to three), while the reactivity to RRM1 and ERCC1
remained unchanged.
MMi15 and MMi16 are from the same primary cell
culture where MMi15 was prepared from papillary
groups and MMi16 from adhered disassociated cells
(Table 1). These two preparations contained similar
amounts of tumor cells, had similar reactivity to RRM1
and ERCC1, and similar resistance to the tested drugs.
Discussion
Chemotherapeutical treatment of malignant mesotheli-
oma continues to be struggling and even though several
different agents and drug combinations have been sug-
gested, the combination of pemetrexed and cisplatin or
carboplatin remains the first line treatment [6,38-40].
The 40% response rate of these treatments is, however,
disappointing and patients responding to treatment have
the longest survival time [8]. This demonstrates the need
for greater understanding of patient response, treatment
effects and markers correlating to these aspects. In cell
lines we have previously seen large differences in sensi-
tivity to different drugs, and in immunoreactivity of
different predictive markers, suggesting a possibility for
personalized treatment [16,41]. By performing more de-
tailed studies of MM patient’s primary malignant cells
we might be able to individualize treatment to increase
response rates and survival times.
In this study we perform an extensive characterization
of primary cells from pleural effusions from patients
with malignant mesothelioma. We observe a large indi-
vidual variability in their drug sensitivity and a wide-
spread resistance (Figures 1, 2A and 3), reflecting the
clinical situation with limited effect of chemotherapy
and a highly individual response rate. The patient sur-
vival time correlated to the proportion of effective drugs
and sensitivity scores (Figure 2C-F) and seems to be in-
fluenced by the proportion of malignant cells and RRM1
reactivity (Figures 2B,F and 5B). RRM1 staining cor-
related to general drug sensitivity of primary cells
(Figure 5A), comparable findings have been seen in non-
small cell lung cancer patients treated with cisplatin and
vinorelbine, where immunohistochemical evaluation of
Figure 3 Drug efficiency and adjusted drug efficiency of primary mesothelioma cells. Nine malignant cell isolates arranged according to
their proportion of malignant cells. R = Resistant, drug efficiency less than 40%. An increasing red color represents increased drug efficiency
(40-60%, 60-80% and 80-100%, respectively). Adjusting the drug efficiency to the proportion of malignant cells and drug effect on benign cells;
seem to increase the sensitivity of cell isolates and effects of several drugs.
A B
C D
100 µm 100 µm
100 µm 100 µm
Figure 4 Immunoreactivity of RRM1 and ERCC1 in primary malignant mesothelioma cells. The panel shows representative micrographs:
(A) weak RRM1 staining intensity (score 1) (B) strong RRM1 staining intensity (score 3) (C) weak ERCC1 staining intensity (score 1) and (D) strong
ERCC1 staining intensity (score 3), respectively. Scale bar = 100 μm.
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Figure 5 RRM1 and ERCC1 immunoreactivity correlated to proportion of effective drugs and survival time. (A) Proportion of effective
drugs plotted against RRM1 staining. (B) Survival time plotted against RRM1. (C) Proportion of effective drugs plotted against ERCC1 staining.
(D) Survival time plotted against ERCC1 Regression analysis presented in red, data points for each patient in blue. Statistically significant departure
of the slope from 0 was accepted at p < 0.05 and seen for proportion of effective drugs and RRM1 immunoreactivity (A).
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http://www.biomedcentral.com/1471-2407/14/709RRM1 predicted drug effect [42]. The observed variability
in chemosensitivity seems to partly depend on the pro-
portion of malignant cells in the samples and RRM1
levels but other factors associated with individual tumor
heterogeneity are probably also important.
Among drugs used in first and second line treatment,
cisplatin, carboplatin and pemetrexed showed little or
no effect on any of the tested malignant cell isolates,
whereas gemcitabine and doxorubicin, affected five and
six of the malignant isolates, respectively. The limited
effect of pemetrexed might be explained by our previous
findings, that cell cycle distribution is a more sensitive
approach when detecting short term effect of this drug
[16]. After correcting for admixture of benign cells and
the average effect of respective drug on the benign cell
cultures, the correlation of drug efficiency to survival
improved. Interestingly, this correlation was most prom-
inent with pemetrexed and cisplatin, the combination
which is today’s first line treatment for MM. However,
several phase II studies have achieved comparable results
using pemetrexed and carboplatin [43,44] as well as the
combination of carboplatin, liposomized doxorubicin
and gemcitabine [45]. These five drugs affect differentcell samples (Figure 3) which indicates that some of the
patients not responding to pemetrexed and cisplatin
treatment might have had a better response if they were
treated with another drug combination. Although not
yet proven, this kind of ex vivo testing of drug sensi-
tivity may provide a basis for personalized choice of
treatment.
Long-term culturing of primary cells may affect the re-
sponse to drug exposure. In one sample, culturing over
18 passages changed the RRM1 reactivity and increased
the general sensitivity to drugs (Figures 2A and 5A), per-
haps associated to sub-cloning. Such an effect was not
seen in a second case grown for seven passages. When
separating cells into disassociated cells and papillary
groups, the latter were less sensitive in one sample
(Table 1 and Figure 1). Culturing patient samples for
several passages or dividing them into disassociated cells
and papillary groups thus may affect the outcome of
testing, indicating the importance to use primary cul-
tures from entire samples.
Pleural effusions obtained from the same patient at
four years interval (Table 1 and Figure 1) show an
increased proportion of malignant cells in the sample.
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drug resistance (Figures 2A-C and 5A), perhaps reflect-
ing a progressed disease.
The proportion of malignant cells in the effusions
seems to have a decisive effect in these experiments, cor-
relating to proportion of effective drugs and affecting
the survival time (Figure 2A, B and F). When we adjust
the efficiency for the proportion of malignant cells and
possible effects on benign cells, we can still see that
patient samples with a lower proportion of malignant
cells are more sensitive to the different drugs (Figures 1
and 3). These results indicate that pleural effusions
from patients with MM where the proportions of
malignant cells are higher might reflect a more advanced
disease, with shorter survival time and extensive drug
resistance. The observed cytotoxic effects on cell lines
corresponded to the effects seen on primary cells, verify-
ing that these cell lines are a suitable model system for
studying primary MM cells.
In a few of the primary cell cultures the used drug
concentrations varied (cf. Table 2). This did, however,
not affect the sensitivity of the primary cells, except
when using fludarabine and topotecan, which showed
increased effects at the higher concentration. ERCC1
staining was not shown to correlate to any of the mea-
sured factors. One cause for this may be that the included
drugs do not affect the DNA directly, since ERCC1 mainly
indicates resistance to DNA affecting drugs.
Conclusions
Our experimental approach allows a simultaneous deter-
mination of ex vivo chemosensitivity of primary malig-
nant mesothelioma cells to 32 different drugs. The
results demonstrate that there are large differences in
drug sensitivity between the different primary cell iso-
lates. Interestingly, drug sensitivity, amount of malignant
cells and RRM1 reactivity seemed to correlate to each
other and to the survival time of the patients. To evalu-
ate the efficiency of individual drugs results should be
adjusted for the proportion of malignant cells, i.e., for
the possible effect on benign cells in the culture. After
this correction, correlations were seen for pemetrexed
and cisplatin effects and survival time. We could also
see that these two drugs affect different cell samples
compared to carboplatin, doxorubicin and gemcitabine,
accentuating the use of these three drugs when first line
treatment fails.
The proportion of malignant cells in the pleural effu-
sions from patients with MM also seems to play an
important role in drug sensitivity and survival time.
These results indicate that higher amount of malig-
nant cells in pleural effusions are seen in patients
with an advanced disease, shorter survival time and ex-
tensive drug resistance.The variability in response to the commonly used
therapeutic alternatives emphasizes the need for tests
that would indicate best individual choice of drugs. Drug
sensitivity assays of cells isolated from an effusion like
the one tested here may provide such an opportunity.
Confounding factors that must be dealt with concerns
the admixture of benign cells and how these cells react
to drug exposure. The trends seen here will be further
evaluated in larger patient cohorts and the reactivity
pattern will be correlated to the effect of the clinically
administered drugs.
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